Global Hepatitis B Virus Testing Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

November 2017 | 210 pages | ID: G8F918CE06CEN
Precision Business Insights (PBI)

Abstracts

Hepatitis B is a liver disease caused by the Hepatitis B virus (HBV). Hepatitis B viral infection ranges can form mild infection which last few weeks and a chronic infection that may lead to liver disorders and even death. Hepatitis B is one of the global health problem. Hepatitis B can cause chronic infection and puts people at high risk of death from cirrhosis and liver cancer. The virus is transmitted through contact with the blood or other body fluids of an infected person. According to World Health Organization, 257 Mn people are living with hepatitis B virus infection worldwide and in 2015, 887 000 hepatitis B resulted deaths.

Increase in liver cancer cases, growing aging population, healthcare spending and urbanization. leading to better monitoring and screening procedures. In addition, government initiatives in growing awareness in public, increase in R&D spending by companies and growing demand for bio marker tests due to its accuracy expected to boost the hepatitis B virus testing market during the forecast period. However, factors such as lack of awareness in developing countries, stringent regulatory rules, rigid competition and high cost of testing are expected to hamper the hepatitis B virus testing market over the forecast period.

The global hepatitis B testing market is classified on the basis of test type, technique end use, and geography.

Based on test type, the global hepatitis B diagnostic test market is segmented into the following:

• Hepatitis B surface antigen test (HBsAg)
• Anti-hepatitis B surface antibody test
• Hepatitis B core antigen test (HBcAb)
• Anti-hepatitis B core antibody test
• HBV DNA test
• Others

Based on techniques, the global hepatitis B diagnostic test market is segmented into the following:

• PCR
• Radioimmunoassay (RIA)
• Enzyme-linked immunosorbent assay (ELISA)
• Others

Based on end-user type, the global hepatitis B diagnostic test market is segmented into the following:

• Hospitals
• Diagnostic centers
• Clinics

Currently, more than 13 immunoassays are available to diagnose hepatitis B virus at an early stage. They can also be used to distinguish acute and chronic hepatitis B infections. Many governments in the European countries and the US made it mandatory for the people to go through the screening and proper monitoring since hepatitis B takes the time to develop and is not easily recognizable. There are some curative therapies available but they are not very efficient. It is expected that many innovative therapies which have shown positive results in trials will occupy the market in the coming years. Many companies have products related to hepatitis B in their pipeline. Vendors are developing devices and systems that help integrate laboratory applications. For instance, in 2010 the COBAS 6000 modular platform by Roche Diagnostics offers optimum efficiency and consolidation in medium- and high-volume laboratories.

Geographically, hepatitis B testing market has been segmented into North America, Europe, Latin America, Asia-Pacific, and The Middle East & Africa. North America dominated the hepatitis B therapeutics market owing to the high awareness levels, availability of improved infrastructure, and favourable government initiatives relating to the promotion of hepatitis B therapeutics. Europe is the second largest market for hepatitis B therapeutics driven by rising geriatric population, high rates of chronic infections in Central and Eastern Europe e European Centre for Disease Prevention and Control (ECDC) estimates an overall hepatitis B incidence of 1.49 per 100 000, prevalence of hepatitis B is the highest in Middle East & Africa where adult population is chronically infected. According to World Health Organization (WHO), 2% to 5% of population is affected with hepatitis B virus in Asia Pacific region. And most people die with liver diseases.

Some of the players hepatitis B testing market are Onsite Lab Holding AG (MedMira Inc.) (Switzerland), F. Hoffmann-La Roche (Switzerland), Abbott Laboratories (USA), Siemens AG (Siemens Healthcare GmbH) (Germany), Fisher Bioblock Bolding (Thermo Fisher Scientific) (France), Innovita biological technology Co. Ltd. (China), General Biologicals Corporation (Taiwan), Nantong Diagnos Biotechnology Co. Ltd. (China), Blue Cross Bio-Medical (China) Co. Ltd., BioGenex (U.S.), and Abnova Corporation (U.S.), among others.

In October 2011, Roche received Premarket Approval from USFDA for its IgM antibody to hepatitis B core antigen (Anti-HBc IgM) assay for use on the Cobas e 601 analyzers, the immunoassay module of the Cobas 6000 (hepatitis B test) analyzer

In September 2010, Abbott received USFDA approval for its RealTime HBV assay, first and only test approved test capable of automating HBV viral load testing

REPORT OUTLINE:

• The report provides granular level information about the market size, regional market share and forecast from 2017-2023
• The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
• The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
• The report tracks recent innovations, key developments and startup’s details that are working in the industry
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL HEPATITIS B VIRUS TESTING MARKET INTRODUCTION

2.1. Global Hepatitis B Virus Testing Market– Taxonomy
2.2. Global Hepatitis B Virus Testing Market–Definitions
  2.2.1. Test Type
  2.2.2. Technique

3. GLOBAL HEPATITIS B VIRUS TESTING MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Hepatitis B Virus Testing Market Dynamics – Factors Impact Analysis
3.6. Global Hepatitis B Virus Testing Market– Recent Market Introductions

4. GLOBAL HEPATITIS B VIRUS TESTING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL HEPATITIS B VIRUS TESTING MARKET FORECAST, BY TEST TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Hepatitis B Surface Antigen Test (HBsAg)
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. Anti-hepatitis B Surface Antibody Test
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis
5.3. Hepatitis B Core Antigen Test (HBcAb)
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.3.3. Market Opportunity Analysis
5.4. Anti-hepatitis B Core Antibody Test
  5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.4.3. Market Opportunity Analysis
5.5. HBV DNA Test
  5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.5.3. Market Opportunity Analysis
5.6. Others
  5.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.6.3. Market Opportunity Analysis

6. GLOBAL HEPATITIS B VIRUS TESTING MARKET FORECAST, BY TECHNIQUE, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. PCR
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Radioimmunoassay (RIA)
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis
6.3. Enzyme-linked immunosorbent assay (ELISA)
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.3.3. Market Opportunity Analysis
6.4. Others
  6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.4.3. Market Opportunity Analysis

7. GLOBAL HEPATITIS B VIRUS TESTING MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Hospitals
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Diagnostic Centers
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis
7.3. Clinics
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.3.3. Market Opportunity Analysis

8. GLOBAL HEPATITIS B VIRUS TESTING MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.1.3. Market Opportunity Analysis
8.2. Europe
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.3.3. Market Opportunity Analysis
8.4. Latin America
  8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
  8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.5.3. Market Opportunity Analysis
8.6. Global Hepatitis B Virus Testing Market- Opportunity Analysis Index - By Technique, By Test Type, By End User, and Region, 2017 – 2023

9. NORTH AMERICA HEPATITIS B VIRUS TESTING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  9.1.1. Technique Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.1.1. PCR
    9.1.1.2. Radioimmunoassay (RIA)
    9.1.1.3. Enzyme-linked immunosorbent assay (ELISA)
    9.1.1.4. Others
  9.1.2. Test Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.2.1. Hepatitis B Surface Antigen Test (HBsAg)
    9.1.2.2. Anti-hepatitis B Surface Antibody Test
    9.1.2.3. Hepatitis B Core Antigen Test (HBcAb)
    9.1.2.4. Anti-hepatitis B Core Antibody Test
    9.1.2.5. HBV DNA Test
    9.1.2.6. Others
  9.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.3.1. Hospitals
    9.1.3.2. Diagnostic Centers
    9.1.3.3. Clinics
  9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    9.1.4.1. U.S.
    9.1.4.2. Canada
  9.1.5. North America Hepatitis B Virus Testing Market- Opportunity Analysis Index - By Technique, By Test Type, By End User, and Country, 2017 – 2023
  9.1.6. North America Hepatitis B Virus Testing Market Dynamics – Trends

10. EUROPE HEPATITIS B VIRUS TESTING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  10.1.1. Technique Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.1.1. PCR
    10.1.1.2. Radioimmunoassay (RIA)
    10.1.1.3. Enzyme-linked immunosorbent assay (ELISA)
    10.1.1.4. Others
  10.1.2. Test Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.2.1. Hepatitis B Surface Antigen Test (HBsAg)
    10.1.2.2. Anti-hepatitis B Surface Antibody Test
    10.1.2.3. Hepatitis B Core Antigen Test (HBcAb)
    10.1.2.4. Anti-hepatitis B Core Antibody Test
    10.1.2.5. HBV DNA Test
    10.1.2.6. Others
  10.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.3.1. Hospitals
    10.1.3.2. Diagnostic Centers
    10.1.3.3. Clinics
  10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.4.1. Germany
    10.1.4.2. UK
    10.1.4.3. France
    10.1.4.4. Spain
    10.1.4.5. Italy
    10.1.4.6. Russia
    10.1.4.7. Poland
    10.1.4.8. Rest of Europe
  10.1.5. Europe Hepatitis B Virus Testing Market- Opportunity Analysis Index - By Technique, By Test Type, By End User, and Country, 2017 – 2023
  10.1.6. Europe Hepatitis B Virus Testing Market Dynamics – Trends

11. ASIA-PACIFIC HEPATITIS B VIRUS TESTING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  11.1.1. Technique Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.1.1. PCR
    11.1.1.2. Radioimmunoassay (RIA)
    11.1.1.3. Enzyme-linked immunosorbent assay (ELISA)
    11.1.1.4. Others
  11.1.2. Test Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.2.1. Hepatitis B Surface Antigen Test (HBsAg)
    11.1.2.2. Anti-hepatitis B Surface Antibody Test
    11.1.2.3. Hepatitis B Core Antigen Test (HBcAb)
    11.1.2.4. Anti-hepatitis B Core Antibody Test
    11.1.2.5. HBV DNA Test
    11.1.2.6. Others
  11.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.3.1. Hospitals
    11.1.3.2. Diagnostic Centers
    11.1.3.3. Clinics
  11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
    11.1.4.1. Japan
    11.1.4.2. China
    11.1.4.3. India
    11.1.4.4. ASEAN
    11.1.4.5. Australia & New Zealand
    11.1.4.6. Rest of Asia-Pacific
  11.1.5. Asia-Pacific Hepatitis B Virus Testing Market- Opportunity Analysis Index - By Technique, By Test Type, By End User, and Country, 2017 – 2023
  11.1.6. Asia-Pacific Hepatitis B Virus Testing Market Dynamics – Trends

12. LATIN AMERICA HEPATITIS B VIRUS TESTING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  12.1.1. Technique Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.1.1. PCR
    12.1.1.2. Radioimmunoassay (RIA)
    12.1.1.3. Enzyme-linked immunosorbent assay (ELISA)
    12.1.1.4. Others
  12.1.2. Test Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.2.1. Hepatitis B Surface Antigen Test (HBsAg)
    12.1.2.2. Anti-hepatitis B Surface Antibody Test
    12.1.2.3. Hepatitis B Core Antigen Test (HBcAb)
    12.1.2.4. Anti-hepatitis B Core Antibody Test
    12.1.2.5. HBV DNA Test
    12.1.2.6. Others
  12.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.3.1. Hospitals
    12.1.3.2. Diagnostic Centers
    12.1.3.3. Clinics
  12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.4.1. Brazil
    12.1.4.2. Mexico
    12.1.4.3. Argentina
    12.1.4.4. Venezuela
    12.1.4.5. Rest of Latin America
  12.1.5. Latin America Hepatitis B Virus Testing Market- Opportunity Analysis Index - By Technique, By Test Type, By End User, and Country, 2017 – 2023
  12.1.6. Latin America Hepatitis B Virus Testing Market Dynamics – Trends

13. MIDDLE EAST & AFRICA HEPATITIS B VIRUS TESTING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  13.1.1. Technique Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.1.1. PCR
    13.1.1.2. Radioimmunoassay (RIA)
    13.1.1.3. Enzyme-linked immunosorbent assay (ELISA)
    13.1.1.4. Others
  13.1.2. Test Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.2.1. Hepatitis B Surface Antigen Test (HBsAg)
    13.1.2.2. Anti-hepatitis B Surface Antibody Test
    13.1.2.3. Hepatitis B Core Antigen Test (HBcAb)
    13.1.2.4. Anti-hepatitis B Core Antibody Test
    13.1.2.5. HBV DNA Test
    13.1.2.6. Others
  13.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.3.1. Hospitals
    13.1.3.2. Diagnostic Centers
    13.1.3.3. Clinics
  13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.4.1. Gulf Cooperation Council (GCC) Countries
    13.1.4.2. Israel
    13.1.4.3. South Africa
    13.1.4.4. Rest of MEA
  13.1.5. MEA Hepatitis B Virus Testing Market- Opportunity Analysis Index - By Technique, By Test Type, By End User, and Country, 2017 – 2023
  13.1.6. MEA Hepatitis B Virus Testing Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  14.2.1. Onsite Lab Holding AG (MedMira Inc.) (Switzerland)
  14.2.2. F. Hoffmann-La Roche (Switzerland)
  14.2.3. Abbott Laboratories (USA)
  14.2.4. Siemens AG (Siemens Healthcare GmbH) (Germany)
  14.2.5. Thermo Fisher Scientific (France)
  14.2.6. Innovita biological technology Co. Ltd. (China)
  14.2.7. General Biologicals Corporation (Taiwan)
  14.2.8. Nantong Diagnos Biotechnology Co. Ltd. (China)
  14.2.9. BioGenex (U.S.)
  14.2.10. Abnova Corporation (U.S.)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS